Free Trial

Phreesia (PHR) Competitors

$22.63
+0.17 (+0.76%)
(As of 05/24/2024 ET)

PHR vs. MPLN, BLTE, OMI, AGTI, KNSA, BKD, BCRX, VIR, AKRO, and GMTX

Should you be buying Phreesia stock or one of its competitors? The main competitors of Phreesia include MultiPlan (MPLN), Belite Bio (BLTE), Owens & Minor (OMI), Agiliti (AGTI), Kiniksa Pharmaceuticals (KNSA), Brookdale Senior Living (BKD), BioCryst Pharmaceuticals (BCRX), Vir Biotechnology (VIR), Akero Therapeutics (AKRO), and Gemini Therapeutics (GMTX). These companies are all part of the "medical" sector.

Phreesia vs.

MultiPlan (NYSE:MPLN) and Phreesia (NYSE:PHR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, community ranking, valuation, earnings, dividends, analyst recommendations and risk.

MultiPlan has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, Phreesia has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

87.2% of MultiPlan shares are held by institutional investors. Comparatively, 92.1% of Phreesia shares are held by institutional investors. 8.2% of MultiPlan shares are held by insiders. Comparatively, 5.8% of Phreesia shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Phreesia has a net margin of -38.42% compared to Phreesia's net margin of -65.83%. Phreesia's return on equity of -8.11% beat MultiPlan's return on equity.

Company Net Margins Return on Equity Return on Assets
MultiPlan-65.83% -8.11% -1.89%
Phreesia -38.42%-53.33%-38.04%

Phreesia received 113 more outperform votes than MultiPlan when rated by MarketBeat users. Likewise, 64.74% of users gave Phreesia an outperform vote while only 41.67% of users gave MultiPlan an outperform vote.

CompanyUnderperformOutperform
MultiPlanOutperform Votes
10
41.67%
Underperform Votes
14
58.33%
PhreesiaOutperform Votes
123
64.74%
Underperform Votes
67
35.26%

MultiPlan has higher revenue and earnings than Phreesia. Phreesia is trading at a lower price-to-earnings ratio than MultiPlan, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MultiPlan$961.52M0.42-$91.70M-$0.98-0.64
Phreesia$356.30M3.66-$136.88M-$2.52-9.04

In the previous week, Phreesia had 2 more articles in the media than MultiPlan. MarketBeat recorded 7 mentions for Phreesia and 5 mentions for MultiPlan. Phreesia's average media sentiment score of 1.03 beat MultiPlan's score of 0.83 indicating that MultiPlan is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MultiPlan
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Phreesia
3 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

MultiPlan presently has a consensus target price of $2.00, indicating a potential upside of 220.26%. Phreesia has a consensus target price of $31.62, indicating a potential upside of 37.58%. Given Phreesia's higher possible upside, research analysts clearly believe MultiPlan is more favorable than Phreesia.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MultiPlan
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Phreesia
0 Sell rating(s)
2 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.86

Summary

MultiPlan beats Phreesia on 9 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PHR vs. The Competition

MetricPhreesiaBusiness services IndustryMedical SectorNYSE Exchange
Market Cap$1.31B$17.96B$5.00B$17.77B
Dividend YieldN/A3.44%2.81%3.49%
P/E Ratio-9.0430.13133.4022.86
Price / Sales3.663.182,452.2610.29
Price / CashN/A22.2535.9519.57
Price / Book5.044.755.435.92
Net Income-$136.88M$490.95M$104.34M$976.39M
7 Day Performance-6.33%-0.96%-1.47%-1.65%
1 Month Performance3.78%1.46%2.64%3.05%
1 Year Performance-26.31%10.77%3.36%22.74%

Phreesia Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MPLN
MultiPlan
0.7155 of 5 stars
$0.54
-1.8%
$2.00
+273.8%
-56.6%$344.80M$961.52M-0.552,800Positive News
Gap Up
BLTE
Belite Bio
0.8035 of 5 stars
$45.42
+0.6%
$44.83
-1.3%
+92.2%$1.35BN/A-38.4920
OMI
Owens & Minor
4.5116 of 5 stars
$17.68
-1.8%
$23.29
+31.7%
-14.8%$1.35B$10.33B-34.6713,700Analyst Downgrade
AGTI
Agiliti
1.7069 of 5 stars
$10.05
-0.5%
$14.17
+41.0%
-41.0%$1.37B$1.17B-71.785,800High Trading Volume
KNSA
Kiniksa Pharmaceuticals
1.6738 of 5 stars
$19.37
-1.5%
$31.00
+60.0%
+39.9%$1.37B$270.26M176.11297
BKD
Brookdale Senior Living
2.819 of 5 stars
$6.90
+0.4%
$7.50
+8.8%
+79.6%$1.33B$3.02B-8.9525,200
BCRX
BioCryst Pharmaceuticals
4.3173 of 5 stars
$6.42
+4.7%
$14.00
+118.1%
-27.8%$1.32B$331.41M-6.00536Positive News
VIR
Vir Biotechnology
2.0108 of 5 stars
$10.21
+5.4%
$33.57
+228.8%
-60.2%$1.39B$43.99M-2.55587Analyst Forecast
News Coverage
AKRO
Akero Therapeutics
3.8107 of 5 stars
$20.24
+0.5%
$41.13
+103.2%
-57.4%$1.40BN/A-6.3358Gap Up
GMTX
Gemini Therapeutics
0 of 5 stars
$32.37
+0.6%
N/A-1.1%$1.40BN/A-32.3731News Coverage

Related Companies and Tools

This page (NYSE:PHR) was last updated on 5/24/2024 by MarketBeat.com Staff

From Our Partners